Sentences with phrase «global security program»

Besides the more traditional duties expected of an in - house lawyer and corporate secretary, Shull's appointment has also seen him jump head - first into CIGI's Global Security Program, contributing research that explores the legality of cyber espionage and the rules of attribution and state responsibility for offensive cyber activities.

Below is a statement by David Wright, co-director of the Global Security Program at the Union of Concerned Scientists.

Hannah Parra is a campaign associate in the Global Security Program at the Union of Concerned Scientists.

Here's the rebuttal, by David Wright, co-director and senior scientist in the group's Global Security Program:

Dr. Edwin Lyman is a Senior Scientist in the Global Security Program at the Union of Concern Scientists (UCS).

North Korea apparently tested the medium - range missile seven times last year, with just one success, said physicist and missile - technology expert David Wright, co-director of the Union of Concerned Scientists» Global Security Program.

David Wright, a physicist and the codirector of the Union of Concerned Scientists» global security program, wrote recently that North Korea's latest missile could likely fly 8,100 miles on a normal trajectory, enough to reach anywhere in the continental US.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

That China has even embarked on an aircraft carrier program speaks volumes about their future role in global security.

On Sunday night, Citizenfour, a film about Edward Snowden holed up in a Hong Kong hotel room revealing the global spying programs run by the U.S. National Security Agency, won the Oscar for best documentary for its chilling portrait of technology and surveillance.

WASHINGTON, Jan 22 (Reuters)- The U.S. Transportation Security Administration said Monday it was requiring six Middle Eastern carriers to participate in an enhanced cargo screening program as part of an effort to raise global aviation sSecurity Administration said Monday it was requiring six Middle Eastern carriers to participate in an enhanced cargo screening program as part of an effort to raise global aviation securitysecurity.

WASHINGTON, Jan 22 - The U.S. Transportation Security Administration said Monday it was requiring six Middle Eastern carriers to participate in an enhanced cargo screening program as part of an effort to raise global aviation sSecurity Administration said Monday it was requiring six Middle Eastern carriers to participate in an enhanced cargo screening program as part of an effort to raise global aviation securitysecurity.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The Carnegie Europe Program in Washington provides insight and analysis on political and security developments within Europe, transatlantic relations, and Europe's global role.

These programs give travelers the convenience of shorter security lines and expedited clearance when traveling into the U.S. (in the case of Global Entry).

First, you receive a $ 100 credit towards the application fee for the Global Entry program, which includes TSA PreCheck expedited domestic security at the airport and priority service when you return to the United States after visiting a foreign country.

This approach has allowed cyber defense programs to overcome the greatest challenge: a global shortage of cyber security talent.

Examples of these risks, uncertainties and other factors include, but are not limited to the impact of: adverse general economic and related factors, such as fluctuating or increasing levels of unemployment, underemployment and the volatility of fuel prices, declines in the securities and real estate markets, and perceptions of these conditions that decrease the level of disposable income of consumers or consumer confidence; adverse events impacting the security of travel, such as terrorist acts, armed conflict and threats thereof, acts of piracy, and other international events; the risks and increased costs associated with operating internationally; our expansion into and investments in new markets; breaches in data security or other disturbances to our information technology and other networks; the spread of epidemics and viral outbreaks; adverse incidents involving cruise ships; changes in fuel prices and / or other cruise operating costs; any impairment of our tradenames or goodwill; our hedging strategies; our inability to obtain adequate insurance coverage; our substantial indebtedness, including the ability to raise additional capital to fund our operations, and to generate the necessary amount of cash to service our existing debt; restrictions in the agreements governing our indebtedness that limit our flexibility in operating our business; the significant portion of our assets pledged as collateral under our existing debt agreements and the ability of our creditors to accelerate the repayment of our indebtedness; volatility and disruptions in the global credit and financial markets, which may adversely affect our ability to borrow and could increase our counterparty credit risks, including those under our credit facilities, derivatives, contingent obligations, insurance contracts and new ship progress payment guarantees; fluctuations in foreign currency exchange rates; overcapacity in key markets or globally; our inability to recruit or retain qualified personnel or the loss of key personnel; future changes relating to how external distribution channels sell and market our cruises; our reliance on third parties to provide hotel management services to certain ships and certain other services; delays in our shipbuilding program and ship repairs, maintenance and refurbishments; future increases in the price of, or major changes or reduction in, commercial airline services; seasonal variations in passenger fare rates and occupancy levels at different times of the year; our ability to keep pace with developments in technology; amendments to our collective bargaining agreements for crew members and other employee relation issues; the continued availability of attractive port destinations; pending or threatened litigation, investigations and enforcement actions; changes involving the tax and environmental regulatory regimes in which we operate; and other factors set forth under «Risk Factors» in our most recently filed Annual Report on Form 10 - K and subsequent filings by the Company with the Securities and Exchange Csecurities and real estate markets, and perceptions of these conditions that decrease the level of disposable income of consumers or consumer confidence; adverse events impacting the security of travel, such as terrorist acts, armed conflict and threats thereof, acts of piracy, and other international events; the risks and increased costs associated with operating internationally; our expansion into and investments in new markets; breaches in data security or other disturbances to our information technology and other networks; the spread of epidemics and viral outbreaks; adverse incidents involving cruise ships; changes in fuel prices and / or other cruise operating costs; any impairment of our tradenames or goodwill; our hedging strategies; our inability to obtain adequate insurance coverage; our substantial indebtedness, including the ability to raise additional capital to fund our operations, and to generate the necessary amount of cash to service our existing debt; restrictions in the agreements governing our indebtedness that limit our flexibility in operating our business; the significant portion of our assets pledged as collateral under our existing debt agreements and the ability of our creditors to accelerate the repayment of our indebtedness; volatility and disruptions in the global credit and financial markets, which may adversely affect our ability to borrow and could increase our counterparty credit risks, including those under our credit facilities, derivatives, contingent obligations, insurance contracts and new ship progress payment guarantees; fluctuations in foreign currency exchange rates; overcapacity in key markets or globally; our inability to recruit or retain qualified personnel or the loss of key personnel; future changes relating to how external distribution channels sell and market our cruises; our reliance on third parties to provide hotel management services to certain ships and certain other services; delays in our shipbuilding program and ship repairs, maintenance and refurbishments; future increases in the price of, or major changes or reduction in, commercial airline services; seasonal variations in passenger fare rates and occupancy levels at different times of the year; our ability to keep pace with developments in technology; amendments to our collective bargaining agreements for crew members and other employee relation issues; the continued availability of attractive port destinations; pending or threatened litigation, investigations and enforcement actions; changes involving the tax and environmental regulatory regimes in which we operate; and other factors set forth under «Risk Factors» in our most recently filed Annual Report on Form 10 - K and subsequent filings by the Company with the Securities and Exchange CSecurities and Exchange Commission.

In tune with this global rhetoric, the United Front Government in its Common Minimum Program made eradication of poverty as its main emphasis along with a seven - point agenda for ensuring safe drinking water, primary education for all, primary health care, housing, food security, road networks and mid-day meals to be implemented by A.D. 2000.

This year food programs have addressed nutrition and food security, food waste has been measured, and a growing group of young leaders have worked to improve the global food system.

In 2015, we migrated to a Global Food Safety Initiative (GFSI) based program in an effort to ensure the very highest attention to the safety and security of the products we provide.

Michele Flournoy, Senior Advisor, Boston Consulting Group; Former Under Secretary of Defense for Policy, US Department of Defense Banning Garrett, Director, Strategic Foresight Initiative, The Brent Scowcroft Center for International Security, Atlantic Council Stephen J. Hadley, Principal, RiceHadleyGates LLC Chuck Hagel, Chairman, Atlantic Council Mikael Hagstrom, Executive Vice President, Europe, Middle East, Africa, and Asia Pacific, SAS Annette Heuser, Executive Director, Bertelsmann Foundation Robert Hormats, Under Secretary of State for Economic Growth, Energy, and Environment, US Department of State David Ignatius, Associate Editor, Washington Post James L. Jones, former National Security Advisor to President Barack Obama Robert Kagan, Senior Fellow, Foreign Policy, Center on the United States and Europe, Brookings Institution Hisham Kassem, Founding Publisher, Al - Masry Al - youm Newspaper Frederick Kempe, President & CEO, Atlantic Council Christopher A. Kojm, Chairman, US National Intelligence Council Marne Levine, Vice President of Global Public Policy, Facebook George Lund, Chairman, Torch Hill Investment Group H.E. Ashok Kumar Mirpuri, Ambassador to the United States, Republic of Singapore Moises Naim, Senior Associate, International Economics Program, Carnegie Endowment for International Peace; Chief International Columnist, El Pais Barry Pavel, Director, The Brent Scowcroft Center for International Security, Atlantic Council Paul Saffo, Managing Director of Foresight, Discern Analytics; Senior Fellow, Strategic Foresight Initiative, The Brent Scowcroft Center for International Security, Atlantic Council Brent Scowcroft, former National Security Advisor to Presidents Gerald Ford and George H.W. Bush James Steinberg, Dean, Maxwell School of Citizenship and Public Affairs, Syracuse University Philip Stephens, Associate Editor, Financial Times Christopher Williams, President, Christopher A. Williams, LLC

«The NRC has been pressured by the nuclear industry, directly and through Congress, to low - ball the potential consequences of a fire because of concerns that increased costs could result in shutting down more nuclear power plants,» said paper co-author Frank von Hippel, a senior research physicist at Princeton's Program on Science and Global Security (SGS), based at the Woodrow Wilson School of Public and International Affairs.

For example, a large body of research has found switching to an entirely vegetarian diet would make a huge difference on the carbon footprint of our food system — the Climate Change, Agriculture and Food Security research program reports that if the global population were to reduce or cut its meat intake, it would halve the cost of mitigation actions needed to stabilize carbon dioxide levels to 450 parts per million by midcentury — but for many people that is not in the cards.

«National security is our number - one priority, and this bill will fund essential programs that maintain our nuclear deterrence posture in the face of growing global threats — including North Korea and other countries that are testing the tolerance of the international community,» House Appropriations Committee Chairman Rodney Frelinghuysen said.

Tags: Borlaug Global Rust Initiative, CGIAR Research Program on Wheat, climate change, Cornell University, Delivering Genetic Gain in Wheat, empowerment, farming systems, female, food security, Front page, gender, India, Jeanie Borlaug Laube Women in Triticum (WIT) Early Career Award, Norman Borlaug, South Asia, stem rust, wheat diseases, women

At USAID there are projects and programs in areas such as global health, food security, water and sanitation, poverty, climate change, environmental degradation, and civil disorder.

Budil has more than 27 years of scientific research and management experience at LLNL across a wide range of Laboratory programs, including Global Security, Weapons and Complex Integration, the National Ignition Facility, and Physical and Life Sciences.

Julie Fischer, PhD, is associate research professor with the department of microbiology and is co-director ofthe Global Health Science and Security program at Georgetown University Medical Center.

He currently serves as Principal Associate Director of Global Security, and is a member of the director's Senior Executive Team supporting the director in the management of Laboratory operations and programs.

Frieden says the CDC in partnership with other countries is accelerating its Global Health Security program, which will increase preparedness worldwide.

Since then, Global Gap Year has evolved somewhat (it's now six countries in 28 weeks), and TBB has launched semester - long programs as well, one focused on food security and public health in Asia and another focused on empowerment and sustainability in South America.

It plans to expand the program to other West African countries and also host a West Africa wide MUN conference Life - Link Friendship Schools Ghana also pioneered a reality TV program called «The Delegate» 7 that aims to promote awareness and understanding of global issues through debates simulated after the UN Security Council.

Bloomberg Philanthropy's Global Scholars program even helps students from different countries collaborate on solving international problems, like water shortages or food security.

Each card comes with our BancorpSouth Rewards program so you can earn points towards travel, gift cards and more with each swipe, plus you'll receive the global purchasing power and security you've come to expect from Visa.

If you find yourself frequently going through airport security, you have no doubt heard of TSA Pre ✔ / Global Entry programs.

These programs give travelers the convenience of shorter security lines and expedited clearance when traveling into the U.S. (in the case of Global Entry).

Platinum members are compensated for applying for either the TSA Pre or Global Entry programs, both expediting the process for travelers going through security and customs at airports.

SAN DIEGO and ALAMEDA, Calif., June 25, 2009 (GLOBE NEWSWIRE)-- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq: MNOV — News) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), and Avigen, Inc. (Nasdaq: AVGN — News), a biopharmaceutical company, today announced that they have confirmed their understanding of certain key terms for a proposed acquisition of Avigen by MediciNova that would combine the companies» broad neurological clinical development programs based on ibudilast (Avigen's AV - 411 and MediciNova's MN - 166).

It comes with a $ 450 annual fee, 100,000 Chase Ultimate Rewards points after spending $ 4,000 in three months, as well as an annual $ 300 rebate on travel expenses and a one - time $ 100 credit for Global Entry, a U.S. Customers and Border Protection program that allows travelers to speed through airport security lines and customs.

American Express also foots the $ 100 bill for U.S. Customs» Global Entry Program, she says, which lets her zip through airport security and skip the U.S. customs line when she travels internationally.

Hot Tip: Before traveling internationally, you should consider the Global Entry program, which will offer you TSA PreCheck to speed up security on the way there plus Global Entry to more quickly clear customs on the way back!

Acceptance into the Global Entry program also includes access to TSA PreCheck, which can certainly expedite security screenings when you're trying to get to a flight.

Effective Wednesday, holders of passports from the Republic of India can apply to join the Department of Homeland Security's Global Entry trusted traveler program.

To lessen the pain while dealing with an ever - increasing number of security risks, the U.S. government created a program called Global Entry that gives pre-approved clearance to low - risk travelers entering the United States.

Medjet is the premier global air medical transport and travel security membership program for travelers.

The TSA chief said that combining the two programs would also make sense in adopting new security - related biometric technologies like the facial recognition effort that CBP is testing for Global Entry.

Currently, members of CBP's Global Entry program are afforded expedited security inspections for domestic trips as automatic participants in TSA PreCheck, but PreCheck members do not have reciprocal Global Entry privileges.

What makes Global Entry even better is that once approved, you automatically get into the TSA's essential PreCheck program, which speeds you through airport security.

Last but not least, cardholders get a credit to cover the costs of applying for Global Entry or TSA Precheck — airport programs that let you skip lines and get expedited security when you fly.